Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DSGN Design Therapeutics	$3.84 -1.8%	$3.74	$2.60 ▼ $7.77	$217.99M	1.62	183,116 shs	65,992 shs
FDMT 4D Molecular Therapeutics	$4.39 -2.4%	$3.45	$2.24 ▼ $28.93	$203.37M	2.84	829,202 shs	486,407 shs
SCPH scPharmaceuticals	$3.95 -1.3%	$2.99	$1.94 ▼ $5.65	$208.53M	0.36	369,031 shs	211,100 shs
STTK Shattuck Labs	$1.01 -5.6%	$0.97	$0.69 ▼ $6.85	$51.25M	1.72	353,758 shs	190,141 shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DSGN Design Therapeutics	-1.79%	-4.24%	+19.63%	-18.30%	+1.86%
FDMT 4D Molecular Therapeutics	-2.44%	+0.92%	+40.26%	+6.81%	-81.76%
SCPH scPharmaceuticals	-1.25%	-5.95%	+76.34%	+30.36%	-2.23%
STTK Shattuck Labs	-5.61%	-11.40%	+11.59%	-15.13%	-84.79%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
DSGN Design Therapeutics	0.6499 of 5 stars	1.0	1.0	0.0	2.7	2.5	0.6
FDMT 4D Molecular Therapeutics	2.9049 of 5 stars	3.3	3.0	0.0	4.0	1.7	0.6
SCPH scPharmaceuticals	4.4426 of 5 stars	3.5	4.0	4.2	3.5	1.7	0.6
STTK Shattuck Labs	2.9876 of 5 stars	3.4	2.0	0.0	3.8	1.7	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
DSGN Design Therapeutics	2.00	Hold	$4.00	4.17% Upside
FDMT 4D Molecular Therapeutics	2.60	Moderate Buy	$29.56	573.25% Upside
SCPH scPharmaceuticals	3.00	Buy	$14.00	254.43% Upside
STTK Shattuck Labs	2.71	Moderate Buy	$7.50	642.57% Upside

Current Analyst Ratings Breakdown

Latest STTK, DSGN, SCPH, and FDMT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/11/2025	FDMT 4D Molecular Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (E+) ➝ Sell (D-)
5/24/2025	FDMT 4D Molecular Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (E+) ➝ Sell (E+)
5/10/2025	FDMT 4D Molecular Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (E+) ➝ Sell (E+)
5/9/2025	FDMT 4D Molecular Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$28.00 ➝ $25.00
5/9/2025	FDMT 4D Molecular Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$51.00 ➝ $44.00
5/9/2025	FDMT 4D Molecular Therapeutics	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$45.00 ➝ $38.00
4/24/2025	FDMT 4D Molecular Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (D-) ➝ Sell (E+)
4/8/2025	FDMT 4D Molecular Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (E+) ➝ Sell (D-)
3/27/2025	STTK Shattuck Labs	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold
3/27/2025	STTK Shattuck Labs	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral
3/22/2025	FDMT 4D Molecular Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (D-) ➝ Sell (E+)

(Data available from 6/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
DSGN Design Therapeutics	N/A	N/A	N/A	N/A	$4.96 per share	N/A
FDMT 4D Molecular Therapeutics	$23K	8,842.03	N/A	N/A	$7.20 per share	0.61
SCPH scPharmaceuticals	$41.98M	4.97	N/A	N/A	$1.04 per share	3.80
STTK Shattuck Labs	$4.61M	10.50	N/A	N/A	$3.41 per share	0.30

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
DSGN Design Therapeutics	-$66.86M	-$0.99	N/A	N/A	N/A	N/A	-18.01%	-17.38%	8/4/2025 (Estimated)
FDMT 4D Molecular Therapeutics	-$100.84M	-$3.18	N/A	N/A	N/A	N/A	-28.00%	-26.16%	8/14/2025 (Estimated)
SCPH scPharmaceuticals	-$54.81M	-$1.91	N/A	N/A	N/A	-264.60%	-244.93%	-68.56%	8/13/2025 (Estimated)
STTK Shattuck Labs	-$87.30M	-$1.39	N/A	N/A	N/A	-1,156.46%	-61.92%	-54.49%	7/30/2025 (Estimated)

Latest STTK, DSGN, SCPH, and FDMT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q1 2025	DSGN Design Therapeutics	-$0.28	-$0.31	-$0.03	-$0.31	N/A	N/A
5/14/2025	Q1 2025	SCPH scPharmaceuticals	-$0.28	-$0.34	-$0.06	-$0.37	$11.63 million	$11.75 million
5/8/2025	Q1 2025	FDMT 4D Molecular Therapeutics	-$0.84	-$0.86	-$0.02	-$0.86	$0.53 million	N/A
5/1/2025	Q1 2025	STTK Shattuck Labs	-$0.29	-$0.27	+$0.02	-$0.27	N/A	N/A
3/27/2025	Q4 2024	STTK Shattuck Labs	-$0.38	-$0.37	+$0.01	-$0.37	$1.00 million	N/A
3/19/2025	Q4 2024	SCPH scPharmaceuticals	-$0.40	-$0.35	+$0.05	-$0.35	$12.08 million	$12.15 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
DSGN Design Therapeutics	N/A	N/A	N/A	N/A	N/A
FDMT 4D Molecular Therapeutics	N/A	N/A	N/A	N/A	N/A
SCPH scPharmaceuticals	N/A	N/A	N/A	N/A	N/A
STTK Shattuck Labs	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
DSGN Design Therapeutics	N/A	34.61	34.61
FDMT 4D Molecular Therapeutics	N/A	17.33	17.33
SCPH scPharmaceuticals	1.66	8.08	6.89
STTK Shattuck Labs	N/A	7.96	7.96

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
DSGN Design Therapeutics	56.64%
FDMT 4D Molecular Therapeutics	99.27%
SCPH scPharmaceuticals	89.52%
STTK Shattuck Labs	58.74%

Insider Ownership

Company	Insider Ownership
DSGN Design Therapeutics	31.20%
FDMT 4D Molecular Therapeutics	9.60%
SCPH scPharmaceuticals	4.78%
STTK Shattuck Labs	12.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
DSGN Design Therapeutics	40	56.77 million	38.96 million	Optionable
FDMT 4D Molecular Therapeutics	120	46.33 million	42.85 million	Optionable
SCPH scPharmaceuticals	30	52.79 million	47.28 million	Optionable
STTK Shattuck Labs	100	47.90 million	42.73 million	Optionable

STTK, DSGN, SCPH, and FDMT Headlines

Recent News About These Companies

Here's Why We're Watching Shattuck Labs' (NASDAQ:STTK) Cash Burn Situation

June 13 at 8:42 AM | finance.yahoo.com

Shattuck Labs, Inc. (NASDAQ:STTK) Receives $7.50 Consensus Target Price from Brokerages

June 5, 2025 | americanbankingnews.com

Shattuck Labs Advances SL-325 Program Amid Financial Progress

May 6, 2025 | tipranks.com

Shattuck Labs Reports First Quarter 2025 Financial Results and Recent Business Highlights

May 1, 2025 | globenewswire.com

Shattuck Labs Announces Participation in Upcoming 24th Annual Needham Virtual Healthcare Conference

April 2, 2025 | globenewswire.com

Shattuck Labs Full Year 2024 Earnings: Misses Expectations

March 29, 2025 | uk.finance.yahoo.com

Shattuck Labs reports Q4 EPS (37c), consensus (32c)

March 29, 2025 | markets.businessinsider.com

H.C. Wainwright Reaffirms Their Hold Rating on Shattuck Labs (STTK)

March 29, 2025 | markets.businessinsider.com

Shattuck Labs, Inc.: Shattuck Labs Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Highlights

March 27, 2025 | finanznachrichten.de

Shattuck Labs Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Highlights

March 27, 2025 | globenewswire.com

Leerink Partners Initiates Coverage of Shattuck Labs (STTK) with Outperform Recommendation

March 18, 2025 | msn.com

Shattuck Labs initiated with an Outperform at Leerink

March 17, 2025 | markets.businessinsider.com

Favourable Signals For Shattuck Labs: Numerous Insiders Acquired Stock

March 11, 2025 | finance.yahoo.com

H.C. Wainwright Keeps Their Hold Rating on Shattuck Labs (STTK)

February 21, 2025 | markets.businessinsider.com

Shattuck Labs’ SL-325 shows positive results in inflammatory bowel disease

February 20, 2025 | markets.businessinsider.com

Shattuck Labs Announces Positive Data from the Preclinical GLP Toxicology Study of SL-325 at the 20th Congress of European Crohn's and Colitis Organization (ECCO) in Inflammatory Bowel Diseases 2025

February 20, 2025 | globenewswire.com

Shattuck Labs to Present Pre-Clinical Data on SL-325 at ECCO 2025 Conference in Berlin

February 13, 2025 | quiverquant.com

Shattuck Labs Announces Oral Presentation at Upcoming 20th Congress of European Crohn's and Colitis Organization (ECCO) in Inflammatory Bowel Diseases 2025

February 13, 2025 | globenewswire.com

Shattuck Labs Announces Poster Presentation at Upcoming 2025 Crohn’s and Colitis Congress

February 4, 2025 | markets.businessinsider.com

Shattuck Labs, Inc. to Present Novel Research on SL-325 at 2025 Crohn’s and Colitis Congress

February 4, 2025 | quiverquant.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

STTK, DSGN, SCPH, and FDMT Company Descriptions

Design Therapeutics NASDAQ:DSGN

$3.84 -0.07 (-1.79%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$3.84 +0.01 (+0.13%)

As of 06/13/2025 04:04 PM Eastern

Design Therapeutics, Inc. a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.

4D Molecular Therapeutics NASDAQ:FDMT

$4.39 -0.11 (-2.44%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$4.40 +0.02 (+0.34%)

As of 06/13/2025 05:50 PM Eastern

4D Molecular Therapeutics, Inc., a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology. Its product pipeline includes 4D-150, which is in phase 1/2 clinical trial for the treatment of wet age-related macular degeneration; and is in phase 1/2 clinical trial for the treatment of diabetic macular edema. The company develops 4D-125, which is in phase 1/2 clinical trial for the treatment of x-linked retinitis pigmentosa; 4D-110, which is in phase 1/2 clinical trial for the treatment of choroideremia; 4D-710, which is in phase 1/2 clinical trial for the treatment cystic fibrosis lung disease; and 4D-310 to treat fabry disease cardiomyopathy and is in phase 1/2 clinical trial. In addition, its product candidates comprises 4D-175, which is in pre-clinical development for the treatment for geographic trophy; and 4D-725 to treat alpha-1 antitrypsin deficiency lung disease and is in pre-clinical development. The company has collaboration and licensing agreements with Arbor Biotechnologies, Inc.; Astellas Gene Therapies, Inc; uniQure biopharma B.V.; and Cystic Fibrosis Foundation. 4D Molecular Therapeutics, Inc. was founded in 2013 and is headquartered in Emeryville, California.

scPharmaceuticals NASDAQ:SCPH

$3.95 -0.05 (-1.25%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$4.10 +0.15 (+3.67%)

As of 06/13/2025 05:42 PM Eastern

scPharmaceuticals Inc., a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX. The company's product pipeline also includes SCP-111 (furosemide injection), an investigational pH neutral aqueous furosemide formulation that is being developed for subcutaneous administration outside of the hospital setting, including patient self-administration in the home; and SCP-111 Autoinjector, an investigational single-entity, drug-device combination product candidate consisting of a prefilled syringe containing SCP-111, preloaded into a commercially available, fixed single dose, disposable, two step mechanical autoinjector. It has a collaboration agreement with West Pharmaceutical Services, Inc. The company was incorporated in 2013 and is headquartered in Burlington, Massachusetts.

Shattuck Labs NASDAQ:STTK

$1.01 -0.06 (-5.61%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$1.01 0.00 (0.00%)

As of 06/13/2025 04:07 PM Eastern

Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. Shattuck Labs, Inc. was incorporated in 2016 and is headquartered in Austin, Texas.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time